- €469.55m
- €736.11m
- €785.69m
- 84
- 47
- 88
- 88
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.89 | ||
| PEG Ratio (f) | 0.51 | ||
| EPS Growth (f) | 30.14% | ||
| Dividend Yield (f) | 1.47% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.24 | ||
| Price to Tang. Book | 1.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.6 | ||
| EV to EBITDA | 7.37 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.86% | ||
| Return on Equity | 6.3% | ||
| Operating Margin | 4.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 816.91 | 712.29 | 732.07 | 753.27 | 785.69 | 854.5 | 925 | -0.1% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -13.55 | -51.53 | +79.46 | n/a | n/a | +46.9 | +26.24 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
Directors
- Marie-Claire Janailhac-Fritsch NEC (66)
- David Hale CEO (53)
- Jerome Estampes CFO
- Philippe Bourrinet SVP
- Sarah Dayre SVP
- Petra Zalabak VPR
- Jared Houk VPR
- Valerie Brissart OTH
- Mathieu Elie OTH
- Gitte Hesselholt OTH
- Jean-Francois Blanc EXB
- Francois Nicolas EXB
- Marion Barbier DRC (62)
- Mark Fouquet DRC (62)
- Eric Guerbet DRC (44)
- Claire Jouault-Massiot DRC (59)
- Celine Lamort DRC (39)
- Nicolas Louvet DRC (45)
- Marc Massiot DRC (60)
- Isabelle Raynal DRC (53)
- Jean-sebastien Raynaud DRC (50)
- Didier Izabel IND (65)
- Thibault Viort IND (48)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 1st, 1968
- Public Since
- January 15th, 1986
- No. of Employees
- 2,920
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Euronext - Paris- Shares in Issue
- 12,622,444
- Address
- 15 rue des Vanesses, Zone Paris Nord II, VILLEPINTE, 93420
- Web
- https://www.guerbet.com/
- Phone
- +33 145915000
- Auditors
- Deloitte & Associes
Upcoming Events for GBT
Similar to GBT
AbL Diagnostics SA
Euronext - Paris
Affluent Medical SAS
Euronext - Paris
Alpha MOS SA
Euronext - Paris
Amplitude Surgical SA
Euronext - Paris
Aton SA
Euronext - Paris
FAQ
What is the Guerbet SA share price?
As of Today at 20:59 UTC, shares in Guerbet SA are trading at €37.20. This share price information is delayed by 15 minutes.
How has the Guerbet SA share price performed this year?
Shares in Guerbet SA last closed at €37.20 and the price had moved by +125.18% over the past 365 days. In terms of relative price strength the Guerbet SA share price has outperformed the FTSE Global All Cap Index by +93.17% over the past year.
What are the analyst and broker recommendations for Guerbet SA?
The overall consensus recommendation for Guerbet SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Guerbet SA dividend yield?
The Guerbet SA dividend yield is 1.34% based on the trailing twelve month period.
Does Guerbet SA pay a dividend?
Last year, Guerbet SA paid a total dividend of €0.50, and it currently has a trailing dividend yield of 1.34%. We do not have any data on when Guerbet SA is to next pay dividends.
When does Guerbet SA next pay dividends?
We do not have data on when Guerbet SA is to next pay dividends. The historic dividend yield on Guerbet SA shares is currently 1.34%.
How do I buy Guerbet SA shares?
To buy shares in Guerbet SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Guerbet SA?
As of the previous close price of €37.20, shares in Guerbet SA had a market capitalisation of €469.55m.
Where are Guerbet SA shares listed?
Here are the trading details for Guerbet SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: GBT
What kind of share is Guerbet SA?
Based on an overall assessment of its quality, value and momentum Guerbet SA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Guerbet SA share price forecast for 2024?
The analyst consensus target price for shares in Guerbet SA is €41.80. That is 12.37% above the last closing price of €37.20.
Analysts covering Guerbet SA currently have a consensus Earnings Per Share (EPS) forecast of €2.62 for the next financial year.
Find out moreWhat is the trend in the Guerbet SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Guerbet SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +9.69%.
As of the last closing price of €37.20, shares in Guerbet SA were trading +16.4% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Guerbet SA PE Ratio?
The Guerbet SA PE ratio based on its reported earnings over the past 12 months is 11.89. The shares last closed at €37.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Guerbet SA?
Guerbet SA's management team is headed by:
- Marie-Claire Janailhac-Fritsch - NEC
- David Hale - CEO
- Jerome Estampes - CFO
- Philippe Bourrinet - SVP
- Sarah Dayre - SVP
- Petra Zalabak - VPR
- Jared Houk - VPR
- Valerie Brissart - OTH
- Mathieu Elie - OTH
- Gitte Hesselholt - OTH
- Jean-Francois Blanc - EXB
- Francois Nicolas - EXB
- Marion Barbier - DRC
- Mark Fouquet - DRC
- Eric Guerbet - DRC
- Claire Jouault-Massiot - DRC
- Celine Lamort - DRC
- Nicolas Louvet - DRC
- Marc Massiot - DRC
- Isabelle Raynal - DRC
- Jean-sebastien Raynaud - DRC
- Didier Izabel - IND
- Thibault Viort - IND